Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.

Blood - 26 Oct 2017

Fitzhugh Courtney D, Cordes Stefan, Taylor Tiffani, Coles Wynona, Roskom Katherine, Link Mary, Hsieh Matthew M, Tisdale John F

Abstract excerpt

Novel curative therapies using genetic transfer of normal globin-producing genes into autologous hematopoietic stem cells (HSCs) are in clinical trials for patients with sickle cell disease (SCD). The percentage of transferred globin necessary to cure SCD is currently not known. In the setting of allogeneic nonmyeloablative HSC transplants (HSCTs), stable mixed chimerism is sufficient to reverse the disease. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemoglobin, Sickle

Share to Homozygote

Share to Myeloid Cells

Share to Tissue Donors

Share to Transplantation Chimera

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 28887325
DOI: 10.1182/blood-2017-03-772392
PMCID: PMC5659067

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.PMID 28887325Read ↗

Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is nowSemantic proximity Read ↗

Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapySemantic proximity Read ↗

Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell diseaseSemantic proximity Read ↗

Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell diseaseSemantic proximity Read ↗

In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantationSemantic proximity Read ↗

Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell DiseaseSemantic proximity Read ↗

Chimerism Patterns of Long-Term Stable Mixed Chimeras Posthematopoietic Stem Cell Transplantation in Patients with Nonmalignant Diseases: Follow-Up of Long-Term Stable Mixed Chimerism PatientsSemantic proximity Read ↗

Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation.Semantic proximity Read ↗

Evidence for ineffective erythropoiesis in severe sickle cell diseaseSemantic proximity Read ↗

Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell DiseaseSemantic proximity Read ↗

A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correctionSemantic proximity Read ↗

Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune toleranceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.